Noble Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-06-2024
- Paid Up Capital ₹ 9.91 M
as on 23-06-2024
- Company Age 41 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.73 Cr
as on 23-06-2024
- Revenue 47802.33%
(FY 2018)
- Profit -1657.10%
(FY 2018)
- Ebitda -1597.30%
(FY 2018)
- Net Worth
- Total Assets 2.40%
(FY 2018)
About Noble Drugs
The Corporate was formerly known as Noble Drugs P Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.91 M.
The company has closed loans amounting to ₹1.73 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vilas Dhamne, Shriram Dhamne, and Dnyaneshwar Dhamne serve as directors at the Company.
- CIN/LLPIN
U24100MH1983PLC029592
- Company No.
029592
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Mar 1983
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Noble Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dnyaneshwar Dhamne  | Managing Director | 20-Nov-1983 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vilas Dhamne | Director | 01-Mar-1996 | Current |
| Shriram Dhamne | Director | 29-Jun-1995 | Current |
Financial Performance of Noble Drugs.
Noble Drugs Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 47802.33% increase. The company also saw a substantial fall in profitability, with a 1657.1% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Noble Drugs?
In 2018, Noble Drugs had a promoter holding of 66.70% and a public holding of 33.30%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Etash Life Sciences Limited Liability Pa RtnershipActive 4 years 3 monthsVilas Dhamne is a mutual person
- Professional Realtors Association Of Nashik PranActive 2 years 7 months
Dnyaneshwar Dhamne is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 06 Mar 2004 | ₹0.67 M | Satisfied |
Bank Of India Creation Date: 23 Jul 2002 | ₹1.70 M | Satisfied |
Bank Of India Creation Date: 18 Jun 2002 | ₹2.37 M | Satisfied |
How Many Employees Work at Noble Drugs?
Unlock and access historical data on people associated with Noble Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Noble Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noble Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
